Skyhawk says its Huntington’s drug improved symptoms in extension to Phase 1/2 trial

Phase 2positiveSKY-0515Positive

AI Analysis

Summary

Skyhawk Therapeutics reported that SKY-0515, its RNA-splicing candidate for Huntington's disease, improved patient symptoms in a Phase 1/2 extension trial with a 1.59-point improvement on the disease scale. The company is advancing the therapy toward pivotal-stage development.

Clinical Trial Data

Phase

Phase 1/2

Primary Endpoint

Met

Outcome Details

1.59-point improvement on disease symptom scale in Phase 1/2 extension trial

Importance:6/10

Sentiment:

0.75

Huntington's diseaseRNA-splicingPhase 1/2 trialpositive datapivotal development

Read the original article

Published by Endpoints News on September 16, 2026 10:56 AM

Read Original